HC Wainwright Lifts Earnings Estimates for Ovid Therapeutics

Ovid Therapeutics Inc. (NASDAQ:OVID) – Equities research analysts at HC Wainwright lifted their Q1 2025 earnings estimates for shares of Ovid Therapeutics in a research report issued to clients and investors on Monday, March 24th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.13) per share for the quarter, up from their previous forecast of ($0.16). HC Wainwright currently has a “Buy” rating and a $3.00 price target on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Ovid Therapeutics’ Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.15) EPS, Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.15) EPS and Q4 2026 earnings at ($0.16) EPS.

Other equities research analysts have also recently issued research reports about the company. BTIG Research cut their price target on Ovid Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a report on Monday. Wedbush restated an “outperform” rating and issued a $3.00 target price (down from $4.00) on shares of Ovid Therapeutics in a report on Wednesday, March 12th. Finally, Oppenheimer upgraded Ovid Therapeutics from a “market perform” rating to an “outperform” rating and set a $4.00 price target on the stock in a report on Wednesday, January 29th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $3.03.

Ovid Therapeutics Price Performance

Ovid Therapeutics stock opened at $0.43 on Wednesday. The firm has a market capitalization of $30.58 million, a price-to-earnings ratio of -0.92 and a beta of 0.29. Ovid Therapeutics has a 52-week low of $0.42 and a 52-week high of $3.45. The company has a fifty day simple moving average of $0.59 and a 200-day simple moving average of $0.92. The company has a quick ratio of 5.66, a current ratio of 5.66 and a debt-to-equity ratio of 0.18.

Ovid Therapeutics (NASDAQ:OVID) last released its earnings results on Tuesday, March 11th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.03. Ovid Therapeutics had a negative return on equity of 39.24% and a negative net margin of 5,142.56%. The business had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.19 million.

Hedge Funds Weigh In On Ovid Therapeutics

A number of hedge funds have recently made changes to their positions in OVID. SG Americas Securities LLC raised its position in Ovid Therapeutics by 83.9% in the fourth quarter. SG Americas Securities LLC now owns 37,636 shares of the company’s stock valued at $35,000 after purchasing an additional 17,172 shares during the period. XTX Topco Ltd lifted its position in shares of Ovid Therapeutics by 46.2% during the third quarter. XTX Topco Ltd now owns 38,230 shares of the company’s stock worth $45,000 after purchasing an additional 12,076 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of Ovid Therapeutics by 49.7% in the fourth quarter. Bank of America Corp DE now owns 56,733 shares of the company’s stock valued at $53,000 after purchasing an additional 18,841 shares during the period. FMR LLC increased its stake in Ovid Therapeutics by 1,907.4% during the 3rd quarter. FMR LLC now owns 50,225 shares of the company’s stock worth $59,000 after buying an additional 47,723 shares during the period. Finally, Velan Capital Investment Management LP purchased a new stake in shares of Ovid Therapeutics during the fourth quarter worth $65,000. Hedge funds and other institutional investors own 72.24% of the company’s stock.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.